ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Significant Increase in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSAGet Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 276,800 shares, an increase of 1,291.0% from the December 31st total of 19,900 shares. Based on an average daily volume of 1,850,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 11.8% of the shares of the company are sold short.

ZyVersa Therapeutics Stock Performance

Shares of ZVSA stock opened at $1.38 on Friday. ZyVersa Therapeutics has a one year low of $0.98 and a one year high of $25.00. The company’s fifty day moving average price is $1.20 and its 200-day moving average price is $2.09.

ZyVersa Therapeutics Company Profile

(Get Free Report)

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.

Featured Articles

Receive News & Ratings for ZyVersa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZyVersa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.